ARROWHEAD RESEARCH (HDP1 MU) stock market data APIs
€53.4246
0(0%)
as of April 1, 2026
Try our APIs with
free plan!
ARROWHEAD RESEARCH Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HDP1.MU.
Prev. Close
53.4246
Open
53.4246
High
53.4246
Low
53.4246
52 wk Range
8.936-61.44
Market Cap
6 485 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News
New
Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Arrowhead Pharmaceuticals r...
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with incre...
SRPT Stock Surges on Promising Early Results From siRNA Programs
Shares of Sarepta Therapeutics SRPT rose 35% on Wednesday after the company announced early clinical data on two experimental siRNA therapies, which were acquired last year as part of a licensing deal...
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
Johnson & Johnson’s restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets. The ch...
Get ARROWHEAD RESEARCH fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
